

Supplementary Table 1 Comparison of clinical and molecular characteristics between Colombian PTC cases (this study) and non-Latino White patients from TCGA (30) and the Johns Hopkins Hospital (JHH) patient Cohort (23).

Clinical feature	Number of patients (%)			P value ¹	
	Colombia N= 141	TGCA N= 160	JHH N= 1051	Colombia vs. TCGA	Colombia vs. JHH
Male gender	28 (19.9)	41 (25.6)	287 (27.3)	0.235	0.066
Mean age (years)	45.9	47.3	46	0.403	0.846
FVPTC subtype	66 (46.8)	24 (15.0)	258 (24.5)	1.74 x 10⁻⁹	2.4 x 10⁻⁸
Mean tumor size (cm)	2.35	NA	1.5	NA	5.8 x 10⁻⁵¹
Vascular invasion	47 (38.2)	NA	158 (15.0)	NA	1.5 x 10⁻¹⁰
LNM	46 (36.2)	68 (47.9)	324 (30.8)	0.053	0.216
ETT	34 (26.2)	50 (32.3)	184 (17.5)	0.260	0.016
Stage III-IV²	42 (30.4)	56 (35.0)	208 (19.8)	0.403	0.004
Individual mutation status					
<i>BRAF</i> mutation	84 (59.6)	112 (70)	358 (34.1)	Reference	
<i>BRAF</i> wild type	57 (40.4)	48 (30)	693 (65.9)	0.058	2.0 x 10⁻⁵
<i>TERT</i> mutation	23 (16.3)	12 (7.5)	130 (12.4)	Reference	
<i>TERT</i> wild type	118 (83.7)	148 (92.5)	921 (87.6)	0.017	0.188
Combined mutation status					
WT / WT	48 (34.0)	47 (29.4)	629 (59.8)	Reference	

<i>BRAF</i> / WT	70 (49.7)	101 (63.1)	292 (27.8)	0.131	1.2 x 10⁻¹⁷
WT / <i>TERT</i>	9 (6.4)	1 (0.6)	64 (6.1)	0.020	0.108
<i>BRAF</i> / <i>TERT</i>	14 (9.9)	11 (6.9)	66 (6.3)	0.624	0.001

Abbreviations: FVPTC: Follicular variant papillary thyroid cancer; LNM: lymph node metastasis; ETT: extra-thyroid extension. ¹Statistically significant two-tailed p-values are shown in bold. ²Based on American Joint Committee on Cancer (AJCC) protocol of classification but including two cases diagnosed before 45y with metastases.